Cardiac Amyloidosis
Cardiac amyloidosis (CA) encompasses a group of disorders characterized by an abnormal accumulation of amyloid fibrils in the heart, leading to impaired cardiac function and ultimately heart failure. While the incidence of immunoglobulin light chains amyloidosis incidence seems stable at 8 to 15.2 cases per million persons (PMP)/year, the incidence and prevalence of wild type transthyretin-CA are steadily increasing, being currently estimated at 14 to 27 cases PMP/year and 30 to 170 cases PMP, respectively. This review explores the dynamic landscape of CA epidemiology and its implications for screening and management strategies.
